BioLife Solutions Announces Manufacturing Agreement With Somahlution LLC

Company to Produce DuraGraft® Tissue Preservation Solution for Storage of Harvested Veins

BOTHELL, Wash., July 17, 2014 -- BioLife Solutions, Inc. (NASDAQ:  BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced the execution of a long-term contract manufacturing services agreement with Somahlution LLC, a Jupiter, Florida-based biotechnology company.

Under the terms of the three-year agreement, BioLife will manufacture DuraGraft, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries.  Unlike existing potentially cyotocidal and clinically-unproven solutions, DuraGraft is the first Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium and its associated architecture. Financial terms of the agreement were not disclosed. 

IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru

IsoRay Raced to Deliver Cesium-131 Seeds to Treat a 7 Year Old Girl Who Was in Desperate Need of Treatment

RICHLAND, WA--( Jul 14, 2014) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.

Dr. Carlos Alvarez, Neurosurgeon at Instituto de Columna y Cerebro in Lima, successfully completed the world's first stereotactic brain implant utilizing Cesium-131 seeds. Dr.Alvarez said "The patient was a 7 year old female who was diagnosed with a 3 centimeter inoperable Glioma brain tumor that was positioned close to the brainstem. Due to the size and tumor location, surgery and delivering high dose radiation using radiosurgery was not an attractive option." Following the procedure Dr. Alvarez reported that there were no postoperative complications and the young girl was awake with no additional neurological deficit.

Global Leader in Oral Cancer Detection Technologies Positioned for Major Gains

LED Medical Diagnostics: new management, new strategies make share price attractive

Vancouver, BC / June 26, 2014 / If you're looking for a play in the medical device sector, there's a good case to make for LED Medical Diagnostics ("LEDMD") (TSX.V: "LMD", OTCQX: "LEDIF", FSE: "LME").

LEDMD operates in the dental imaging market, which consists of devices and software used in diagnosing and treating dental diseases and conditions. The offerings within this market include items such as digital radiology and optical imaging devices , Cone Beam CT scanners and CAD/CAM systems,. The global market for these goods was valued at $4.5 billion in 2011 and is expected to grow at a CAGR of 5.8% from 2011 to 2016.

FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain

Key Step Towards Entering Consumer Healthcare Market

WALTHAM, Mass.--- NeuroMetrix, Inc. (NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use.

The Company is in late stage development of a consumer oriented chronic pain treatment product. The device is based on wearable technology, presently deployed in the Company’s SENSUS® Pain Management System, that utilizes comfortable, non-invasive electrical stimulation of sensory nerves to induce safe and effective pain relief. It is lightweight and can be worn during the day while active, and at night while sleeping. This 510(k) clearance allows the Company to market the over-the-counter device through retail distribution channels without a prescription requirement.

IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System

Liquid Cesium-131 Provides a Very Homogenous Dose of Radiation Required in the Treatment of Recurrent Brain Cancers

RICHLAND, WA--(Marketwired - Jun 24, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex®) which recently was FDA cleared for internal radiation therapy.